Evidence map›Paper›PMID 42890246›Full record

ArticleFrontiers in immunology2026

Chronic XBP1s-mediated activation of the unfolded protein response impairs CD8

Keith Alan Nair, Jessica Lee, Olivia Zaleski, Luciano Mazzoccoli, Brian Deng, Chih-Chi Andrew Hu, Stanley Ching-Cheng Huang, Andreas Wieland, Hazem E Ghoneim, Haitao Wen and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keith Alan NairDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Jessica LeeDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Olivia ZaleskiDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Luciano MazzoccoliDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Brian DengDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Chih-Chi Andrew HuHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States.
Stanley Ching-Cheng HuangThe Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Andreas WielandThe Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Hazem E GhoneimThe Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Haitao WenThe Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Xiaopei HuangDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Bei LiuDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Targeting ER stress response in B-cell chronic lymphocytic leukemiaR01CA163910 · NCI · WISTAR INSTITUTE · PI Chih-Chi Andrew Hu · 2013 to 2026
$4.8M
Mechanism of gp96/grp94 in regulating plasma cells and myelomaR01CA193939 · NCI · OHIO STATE UNIVERSITY · PI LIU, BEI · 2016 to 2020
$1.7M
Investigating the Mitochondrial Reprogramming Mechanism in Tumor-Associated Macrophages to Counteract ImmunosuppressionR01CA304577 · NCI · OHIO STATE UNIVERSITY · PI Stanley Ching-Cheng Huang · 2026 to 2026
$622k
Understanding Metabolic Reprogramming in Reparative MacrophagesR35GM161784 · NIGMS · OHIO STATE UNIVERSITY · PI Stanley Ching-Cheng Huang · 2026 to 2026
$433k
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA163910NCI NIH HHS R01 CA193939NCI NIH HHS R01 CA304577NIGMS NIH HHS R35 GM161784
6 · The paper itself

Abstract

CD8

Indexed as

CD8-Positive T-LymphocytesUnfolded Protein ResponseX-Box Binding Protein 1AnimalsEndoribonucleasesLymphocyte ActivationMiceMice, Inbred C57BLProtein Serine-Threonine KinasesSignal TransductionT-Cell ExhaustionTumor MicroenvironmentEndoribonucleasesErn1 protein, mouseProtein Serine-Threonine KinasesX-Box Binding Protein 1Xbp1 protein, mouseanti-tumor immunityCD8+ T cellsT cell exhaustionunfolded protein responseXBP1s

Identifiers

PMID42890246
PMCPMC13672639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.